JP Morgan Chase
CSTL icon

JP Morgan Chase’s Castle Biosciences CSTL Stock Holding History

JP Morgan Chase’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Sell
88,771
-1,261
-1% -$41.3K ﹤0.01% 4070
2025
Q4 		$3.5M Buy
90,032
+62,254
+224% +$2.01M ﹤0.01% 3638
2025
Q3 		$633K Buy
27,778
+1,115
+4% +$22.6K ﹤0.01% 4890
2025
Q2 		$544K Sell
26,663
-3,914
-13% -$72.5K ﹤0.01% 4733
2025
Q1 		$612K Sell
30,577
-77,359
-72% -$1.92M ﹤0.01% 4653
2024
Q4 		$2.88M Buy
107,936
+38,527
+56% +$1.17M ﹤0.01% 3870
2024
Q3 		$1.98M Buy
69,409
+43,241
+165% +$1.1M ﹤0.01% 4017
2024
Q2 		$570K Sell
26,168
-49,975
-66% -$1.11M ﹤0.01% 4616
2024
Q1 		$1.69M Buy
76,143
+25,777
+51% +$561K ﹤0.01% 3977
2023
Q4 		$1.09M Sell
50,366
-2,297
-4% -$40.4K ﹤0.01% 4276
2023
Q3 		$889K Buy
52,663
+1,165
+2% +$20.4K ﹤0.01% 4128
2023
Q2 		$707K Buy
51,498
+7,170
+16% +$145K ﹤0.01% 4283
2023
Q1 		$1.01M Buy
44,328
+8,930
+25% +$218K ﹤0.01% 4041
2022
Q4 		$833K Buy
35,398
+2,449
+7% +$56.8K ﹤0.01% 4177
2022
Q3 		$860K Buy
32,949
+2,826
+9% +$79.2K ﹤0.01% 4118
2022
Q2 		$661K Buy
30,123
+5,799
+24% +$135K ﹤0.01% 4382
2022
Q1 		$1.09M Buy
24,324
+754
+3% +$31.2K ﹤0.01% 4196
2021
Q4 		$1.01M Buy
23,570
+1,477
+7% +$77.2K ﹤0.01% 4374
2021
Q3 		$1.47M Buy
22,093
+4,899
+28% +$345K ﹤0.01% 4022
2021
Q2 		$1.26M Sell
17,194
-15,078
-47% -$996K ﹤0.01% 4133
2021
Q1 		$2.21M Buy
32,272
+9,802
+44% +$737K ﹤0.01% 3649
2020
Q4 		$1.51M Buy
22,470
+13,903
+162% +$754K ﹤0.01% 3692
2020
Q3 		$433K Sell
8,567
-1,698
-17% -$75.5K ﹤0.01% 4044
2020
Q2 		$387K Sell
10,265
-2,277
-18% -$77.8K ﹤0.01% 3958
2020
Q1 		$374K Buy
12,542
+10,855
+643% +$328K ﹤0.01% 3964
2019
Q4 		$58K Buy
1,687
+476
+39% +$11.6K ﹤0.01% 5075
2019
Q3 		$22K Buy
+1,211
New +$26.8K ﹤0.01% 5390

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's CSTL Position: Q1 2026 in Review

JP Morgan Chase reduced its Castle Biosciences (CSTL) stake by 1.4% in Q1 2026, selling an estimated $41.3K and leaving 88,771 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4070.

JP Morgan Chase first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $3.5M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • JP Morgan Chase held 88,771 shares of Castle Biosciences worth $2.09M as of Q1 2026.
  • JP Morgan Chase sold 1,261 Castle Biosciences shares in Q1 2026, an estimated $41.3K.
  • Castle Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4070 holding.
  • JP Morgan Chase first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Castle Biosciences position peaked at $3.5M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.